Clinical Trial

A Observational Study to Evaluate the Efficacy and Safety of Pacitol Inj.

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 12, 2024 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evaluate the efficacy and safety of pacitol Inj.(paricalcitol) for secondary hyperparathyroidism with stage 5D chronic kidney disease (CKD 5D) receiving hemodialysis
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-11-06; most recent amendment 2024-12-10.
Trial Details
NCT Number NCT06126016
Lead Sponsor Boryung Pharmaceutical Co., Ltd
Conditions Chronic Kidney Disease 5D, Secondary Hyperparathyroidism
Enrollment 1,000 participants
Start Date 2023-10-19
Primary Completion 2026-04 (estimated)
Study Completion 2026-04 (estimated)
Updated on ClinicalTrials.gov 2024-12-12